Early stopping of cancer clinical trials

Handbook of Statistics in Clinical Oncology: Second Edition

Volumn , Issue , 2005, Pages 227-246

  Dignam, James J ^a   Bryant, John ^b   Wieand, H Samuel ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 40949154458     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (50)

1. Tsiatis, A.A. The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. Biometrika, 68, 311, 1981.
2. Tsiatis, A.A. Repeated significance testing for a general class of statistics used in censored survival analysis. J. Am. Stat. Assoc., 77, 855, 1982.
3. Gail, M.H., DeMets, D.L., and Slud, E.V. Simulation studies on increments of the two-sample logrank score test for survival time data, with application to group sequential boundaries. In Survival Analysis, Crowley, J. and Johnson, R.A., eds., Hayward, CA: Institute of Mathematical Statistics Lecture Notes-Monograph Series, vol. 2, 1982, 287-301.
4. Armitage, P., McPherson, C.K., and Rowe, B.C. Repeated significance tests on accumulating data. J. Royal Stat. Soc. Series A, 132, 235, 1969.
5. Haybittle, J.L. Repeated assessment of results in clinical trials in cancer treatments. Br. J. Radiol., 44, 793, 1971.
6. Pocock, S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika, 64, 191, 1977.
7. Pocock, S.J. Interim analyses for randomized clinical trials: the group sequential approach. Biometrics, 38, 153, 1982.
8. O'Brien, P.C. and Fleming, T.R. A multiple testing procedure for clinical trials. Biometrics, 35, 549, 1970.
9. Wang, S.K. and Tsiatis, A.A. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics, 43, 193, 1987.
10. Fleming, T.R., Harrington, D.P., and O'Brien, P.C. Designs for group sequential tests. Control. Clin. Trials, 5, 348, 1984.
11. DeMets, D.L. and Ware, J.H. Group sequential methods for clinical trials with a onesided hypothesis. Biometrika, 67, 651, 1980.
12. Wald, A. Sequential Analysis. New York: John Wiley and Sons, 1947.
13. DeMets, D.L. and Ware, J.H. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika, 69, 661, 1982.
14. Whitehead, J. and Stratton, I. Group sequential clinical trials with triangular continuation regions. Biometrics, 39, 227, 1983.
15. Whitehead, J. and Jones, D. The analysis of sequential clinical trials. Biometrika, 66, 443, 1979.
16. Whitehead J. The Design and Analysis of Sequential Clinical Trials. Rev. 2nd ed. Chichester: Wiley 1997.
17. Whitehead, J. and Matsushita, T. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment. Stat. Med., 22, 677, 2003.
18. Jennison, C. Efficient group sequential tests with unpredictable group sizes. Biometrika, 74, 155, 1987.
19. Lan, K.K.G. and DeMets, D.L. Discrete sequential boundaries for clinical trials. Biometrika, 70, 659, 1983.
20. Emerson, S.S. and Fleming, T.R. Symmetric group sequential test designs. Biometrics, 45, 905, 1989.
21. Pampallona, S. and Tsiatis, A.A. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J. Stat. Plan. Infer., 42, 19, 1994.
22. Wieand, S., Schroeder, G., and O'Fallon, J.R. Stopping when the experimental regimen does not appear to help. Stat. Med., 13, 1453, 1994.
23. Ellenberg, S.S. and Eisenberger, M.A. An efficient design for phase III studies of combination chemotherapies. Cancer Treatment Rep., 69, 1147, 1985.
24. Wieand, S. and Therneau, T. A two-stage design for randomized trials with binary outcomes. Control. Clin. Trials, 8, 20, 1987.
25. Lan, K.K.G., Simon, R., and Halperin, M. Stochastically curtailed tests in long-term clinical trials. Commun. Stat. - Sequent. Anal., 1, 207, 1982.
26. Halperin, M. et al. An aid to data monitoring in long-term clinical trials. Control. Clin. Trials, 3, 311, 1982.
27. Lan, K.K.G. and Wittes, J. The B-value: a tool for monitoring data. Biometrics, 44, 579, 1988.
28. Davis, B.R. and Hardy, R.J. Upper bounds for type I and type II error rates in conditional power calculations. Commun. Stat. Theory Meth., 19, 3571, 1991.
29. Emerson, S.S., Kittelson, J.M., and Gillen, D.L. Evaluation of Group Sequential Clinical Trial Designs (November 7, 2003). UW Biostatistics Working Paper Series. Working Paper 216. http://www.bepress.com/uwbiostat/paper216.
30. Spiegelhalter, D.J., Freedman, L.S., and Blackburn, P.R. Monitoring clinical trials: conditional or predictive power? Control. Clin. Trials, 7, 8, 1986.
31. Choi, S.C. and Pepple, P.A. Monitoring clinical trials based on predictive probability of significance. Biometrics, 45, 317, 1989.
32. Jennison, C. and Turnbull, B.W. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat. Sci., 5, 299, 1990.
33. Kass, R. and Greenhouse, J. Comment on "Investigating therapies of potentially great benefit: ECMO" by J. Ware. Stat. Sci., 4, 310, 1989.
34. Spiegelhalter, D.J., Freedman, L.S., and Parmar, M.K.B. Bayesian approaches to randomized trials (with discussion). J. Royal Stat. Soc. Series A, 157, 357, 1994.
35. Freedman. L.S., Spiegelhalter, D.J., and Parmar, M.K.B. The what, why, and how of Bayesian clinical trials monitoring. Stat. Med., 13, 1371, 1994.
36. Greenhouse, J. and Wasserman, L. Robust Bayesian methods for monitoring clinical trials. Stat. Med., 14, 1379, 1994.
37. Berry D.A., Stangl D.K., eds. Bayesian Biostatistics. New York: Marcel Dekker, 1996.
38. Parmar, M.K.B., Ungerleider, R.S., and Simon, R. Assessing whether to perform a confirmatory randomized clinical trial. J. Natl. Cancer Inst., 88, 1645, 1996.
39. Fisher, B. et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst., 88, 1529, 1996.
40. Swain, S.M. Tamoxifen: the long and short of it. J. Natl. Cancer Inst., 88, 1510, 1996.
41. Peto, R. Five years of tamoxifen - or more? J. Natl. Cancer Inst., 88, 1791, 1996.
42. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J. Natl. Cancer Inst., 88, 1834, 1996.
43. Dignam, J.J. et al. Early stopping of a clinical trial when there is evidence of no treatment benefit: Protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control. Clin. Trials, 19, 575, 1998.
44. Fisher, B. et al. Five versus more than five years of tamoxifen for lymph node negative breast cancer patients: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer Inst., 93, 684, 2001.
45. Stewart, H.J., Prescott, R.J., and Forrest, A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J. Natl. Cancer Inst., 93, 456, 2001.
46. Emerson, S.S. Statistical packages for group sequential methods. Am. Stat., 50, 183, 1996.
47. SAS Technical Report P-217, SAS/STAT Software: the PHREG Procedure, Version 6, Cary, NC: SAS Institute Inc., 1991. 63 pp.
48. Parmar, M.K.B. et al. Monitoring of large randomized clinical trials: a new approach with Bayesian methods. Lancet, 358, 375, 2001.
49. Freidlin, B. and Korn, E.L. A comment on futility monitoring. Control. Clin. Trials, 23, 355, 2002.
50. Jennison, C. and Turnbull, B.W. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC Press, 2000.